Sign in to view content

Therapies for Diabetic Macular Edema: What’s in the Pipeline?

Peter K. Kaiser, MD FASRS

Video
Published 2018

Related

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting
Marko Lukic, MD PhD FEBO FASRS
On Demand Cases, Courses, and Papers
2019
Outcomes of Patients with DME and Baseline BCVA 20/50 or Worse or 20/40 or Better Treated with Aflibercept 8 mg and 2 mg in the Phase 2/3 PHOTON Trial
Diana V Do, MD, FASRS
Updates from the Field
2024
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022

Category: Diabetic Retinopathy

See more